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Abstract: With the growing body of knowledge on the contribution of efflux activity to
Mycobacterium tuberculosis drug resistance, increased attention has been given to the use of
efflux inhibitors as adjuvants of tuberculosis therapy. Here, we investigated how efflux activity
modulates the levels of efflux between monoresistant and multi- and extensively drug resistant
(M/XDR) M. tuberculosis clinical isolates. The strains were characterized by antibiotic susceptibility
testing in the presence/absence of efflux inhibitors, molecular typing, and genetic analysis of
drug-resistance-associated genes. Efflux activity was quantified by real-time fluorometry. The results
demonstrated that all the M. tuberculosis clinical strains, susceptible or resistant, presented a faster,
rapid, and non-specific efflux-mediated short-term response to drugs. The synergism assays
demonstrated that the efflux inhibitors were more effective in reducing the resistance levels in
the M/XDR strains than in the monoresistant strains. This indicated that M/XDR strains presented a
more prolonged response to drugs mediated by efflux compared to the monoresistant strains, but
both maintain it as a long-term stress response. This work shows that efflux activity modulates the
levels of drug resistance between monoresistant and M/XDR M. tuberculosis clinical strains, allowing
the bacteria to survive in the presence of noxious compounds.
Keywords: efflux inhibitors; lineages; mutations; resistance levels; tuberculosis; verapamil
1. Introduction
Tuberculosis (TB) is a major public health problem worldwide, accounting for an estimated
10.4 million new cases and 1.3 million deaths in 2016 [1]. Despite worldwide efforts to reduce the global
burden of tuberculosis, multidrug resistant (MDR) and extensively drug resistant (XDR) tuberculosis
(continue to increase, leaving very limited therapeutic options for these patients. The emergence of
MDR (simultaneous resistance to isoniazid and rifampicin) and XDR (MDR with additional resistance
to second-line injectables and fluoroquinolones) Mycobacterium tuberculosis has become a major public
health concern worldwide. There was an estimate of 490,000 new MDRTB cases with approximately
200,000 deaths in 2016. Among these, 6.2% were anticipated to be XDRTB cases [1].
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M. tuberculosis develops drug resistance mainly by mutations in genes that code for the
drug targets [2], the impermeability of its cell wall, and the activity of efflux pumps [3–8].
Resistance mediated by efflux has been described as an important contributor to drug resistance in
several bacterial pathogens [9]. Efflux pumps are transmembrane proteins involved in the extrusion of
noxious compounds and cellular metabolites from the cells into the external environment, using cellular
energy derived from ATP (Adenosine triphosphate) or the proton motive force [10]. They are associated
with the transport of a wide range of structurally unrelated antimicrobials, preventing them from
reaching their targets and being responsible for the development of MDR phenotypes [11]. These MDR
phenotypes are dependent of the constitutive or inducible expression of their efflux systems [3,11,12]
where the antibiotics act like inducers through the regulation of the expression of efflux pumps [13].
The role of efflux mechanisms in drug resistance in M. tuberculosis has been demonstrated over
the last years [6–8,14,15]. Some of these putative efflux pumps have been associated with the transport
of fluoroquinolones, isoniazid, rifampicin, ethambutol, β-lactams, doxorubicin, aminoglycosides,
macrolides, tetracycline, and dyes, among others. Of note is that the resistance by efflux was already
described as being involved in the M. tuberculosis resistance to bedaquiline, the most recent drug
approved for the treatment of MDRTB [16]. Our previous works showed that the efflux pumps Mmr,
MmpL7, Rv1258c, P55, Rv1218c-Rv1217c, Rv2459, and EfpA are overexpressed in the presence of
antibiotics, demonstrating the contribution of these pumps to a genotype-independent resistance
phenotype [17,18]. The stress imposed by a subinhibitory antibiotic concentration results in an
increased efflux activity, allowing the selection of spontaneous mutants with clinically significant
resistance levels [7,19,20].
The demonstration of the involvement of efflux pumps on the emergence of M. tuberculosis drug
resistance makes these proteins interesting targets for the discovery of novel drugs. Because efflux is
an important contributor to drug resistance, the identification and characterization of mycobacterial
efflux inhibitors is an approach for the development of new effective antituberculosis therapies.
Efflux inhibitors have been shown to potentiate the activity of several antituberculosis drugs.
Compounds like thioridazine and verapamil have efflux inhibitory properties and inhibit the in vitro
and ex vivo growth of M. tuberculosis strains alone or in combination with antimycobacterial
drugs [17,19,21–23]. Thioridazine has demonstrated significant activity against MDRTB in a murine
model of infection [24] and it has been successfully employed to treat XDRTB patients on the basis of
compassionate reasons [25]. Verapamil has been shown to be the most potent mycobacterial efflux
inhibitor to date, being able to enhance the inhibitory activity of isoniazid [19] and rifampicin [26]
in M. tuberculosis clinical strains. Recently, it was demonstrated that efflux inhibition promoted by
verapamil can potentiate the activity of bedaquiline [27]. It was also showed that the addition of
verapamil accelerates the bactericidal and sterilising activities of tuberculosis therapy in a mouse
model [28]. Beyond their antimycobacterial activity, these compounds also present immunomodulatory
abilities on M. tuberculosis-infected macrophages and efflux inhibitors can enhance the killing of
M. tuberculosis by macrophages [17,29,30]. Further evidence in favour of the usefulness of these
compounds is reported in the studies by Adams et al. [22,23], wherein the selective pressure exerted
by the macrophage on internalized M. tuberculosis-induced bacterial efflux pumps and thereby
drug-tolerance. Additionally, these authors also showed that the macrophage drug-induced tolerance
can be reduced by verapamil or its metabolites. Despite this, little is known about how the efflux
activity influences the resistance levels among different M. tuberculosis lineages and different drug
resistant mutational backgrounds.
Previously, we showed that the drug resistant phenotypes in M. tuberculosis are a combination
of drug efflux and the presence of target-gene mutations, and that the efflux activity modulates the
levels of antibiotic resistance by complementing the resistance due to the presence of target-gene
mutations [18]. Our results demonstrated the existence of a broad-spectrum synergistic interaction
between antibiotics and efflux inhibitors. However, we also noted that the efflux inhibitors were
more active in reducing the minimum inhibitory concentration (MIC) values of isoniazid, rifampicin,
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or both in MDR and XDR M. tuberculosis strains overexpressing efflux pumps than in the monoresistant
strains [18]. This data seems to indicate that the efflux activity may be strain-dependent and the efflux
inhibitors exert their greatest effect on strains with increased efflux activity. The purpose of the present
work is to study the correlation between the effect of efflux inhibitors and the genetic background,
drug resistance profile and efflux activity in clinical strains of M. tuberculosis in order to describe how
the efflux activity modulates the levels of resistance in strains presenting different drug-resistance
associated mutations and genetic backgrounds. Understanding the dynamic underlying bacterial
antibiotic-induced systems could provide a route for new chemotherapeutic approaches.
2. Results
2.1. Characterization of the M. tuberculosis Strains According to Their Efflux Capacity
The 18 M. tuberculosis strains were firstly characterized according to their efflux capacity using
a fluorometric method that detects in real-time the accumulation and efflux of ethidium bromide in
bacterial cells loaded with this fluorophore [19,31,32]. For this purpose, we selected a panel of susceptible,
monoresistant, and M/XDR M. tuberculosis clinical isolates. These strains were chosen in order to
include the most prevalent mutations associated with resistance to isoniazid and rifampicin. As controls,
we selected three pan-susceptible M. tuberculosis strains and the H37Rv reference strain (Table 1).
Figure 1 illustrates the results of the ethidium bromide fluorometric assays and the parameters
used to characterize the efflux capacity of the 18 M. tuberculosis strains, giving as example the results
obtained for strain H37Rv.









INH RIF INH RIF VP TZ
H37Rv H37Rv Suscep. wt wt 0.1 1 256 15
Mtb1 LAM9—Orphan Suscep. wt wt 0.1 1 256 30
Mtb2 Unknown—SIT105 Suscep. wt wt 0.1 1 256 15
Mtb3 T1—SIT612 INHR katG S315T wt 10 1 256 15
Mtb4 LAM1—SIT20 INHR inhA C-15T wt 0.4 1 256 15
Mtb5 LAM2—SIT53 RIFR wt rpoB H526D 0.1 320 256 15
Mtb6 Beijing—SIT1 RIFR wt rpoB H526Y 0.1 320 128 15
Mtb7 LAM1—SIT2576 RIFR wt rpoB S531L 0.1 320 256 15
Mtb8 LAM1—SIT2576 RIFR wt rpoB S531L 0.1 640 256 15
Mtb9 LAM1—SIT20 MDR inhA C-15T/S94A rpoB D516V 3 20 256 15
Mtb10 T1—SIT53 MDR katG S315N rpoB H526Y 3 20 256 15
Mtb11 T1—SIT53 MDR katG S315T rpoB S531L 10 640 256 15
Mtb12 T2—Orphan MDR katG S315T rpoB S531L 10 160 128 15
Mtb13 LAM1—SIT20 MDR inhA C-15T/S94A rpoB S531L 3 320 256 15
Mtb14 Beijing—SIT1 MDR katG S315T rpoB S531L 20 320 256 15
Mtb15 LAM1—SIT20 XDR inhA C-15T/S94A rpoB S531L 20 80 128 15
Mtb16 LAM4—SIT1106 XDR inhA C-15T/I194T rpoB S531L 3 320 256 15
Mtb17 LAM4—SIT1106 XDR inhA C-15T/I194T rpoB S531L 3 320 256 15
Spoligotype SIT/clades were defined according to the international spoligotype database SITVITWEB rules.
“Unknown” designates patterns with signatures that do not belong to any of the major lineages defined in the
SITVITWEB database. The lowest concentration of antibiotic tested corresponded to the critical concentration
of each drug. DST, drug susceptibility testing; MIC, minimum inhibitory concentration; INH, isoniazid; LAM,
Latin American–Mediterranean; MDR, multidrug resistant; RIF, rifampicin; SIT, spoligotype international type;
XDR, extensively drug resistant; VP, verapamil; TZ, thioridazine; Suscep., susceptible; R, resistant; wt, wild-type
sequence; STD, antibiotic susceptibility testing.
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Figure 1. Schematic representation of parameters used for the characterization of the efflux activity 
of the M. tuberculosis strains. Presented in the Figure are the results obtained for the H37Rv strain.  
(A) SpanEtBr corresponds to the difference between the ethidium bromide fluorescence values at t0 
of the highest concentration tested (Yhc) and the fluorescence value at t0 of the equilibrium 
concentration of ethidium bromide (Yeqc); (B) RFF (relative final fluorescence) is a measure of how 
effective a compound is on the inhibition of ethidium bromide efflux (at a given concentration) by 
comparison of the final fluorescence at the last time point (60 min) of the treated cells with the cells in 
presence of ethidium bromide only [19,32]; (C) efflux rate constant, or K value, and the tefflux50% that 
corresponds to the time required for the cells to extrude half of the preloaded dye; the efflux of 
ethidium bromide is initiated at t0 by the addition of 0.4% glucose and is 50% complete at tefflux50%. 
Figure 1. Schematic representation of parameters used for the characterization of the efflux activity
of the M. tuberculosis strains. Presented in the Figure are the results obtained for the H37Rv strain.
(A) SpanEtBr corresponds to the difference between the ethidium bromide fluorescence values at t0 of
the highest concentration tested (Yhc) and the fluorescence value at t0 of the equilibrium concentration
of ethidium bromide (Yeqc); (B) RFF (relative final fluorescence) is a measure of how effective a
compound is on the inhibition of ethidium bromide efflux (at a given concentration) by comparison of
the final fluorescence at the last time point (60 min) of the treated cells with the cells in presence of
ethidium bromide only [19,32]; (C) efflux rate constant, or K value, and the tefflux50% that corresponds
to the time required for the cells to extrude half of the preloaded dye; the efflux of ethidium bromide is
initiated at t0 by the addition of 0.4% glucose and is 50% complete at tefflux50%.
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Initially we determined the SpanEtBr index as a measure of the capacity of each strain to
accumulate ethidium bromide. This value corresponds to the difference between the ethidium bromide
fluorescence values at t0 of the highest concentration tested (Yhc) and the fluorescence value at
t0 of the equilibrium concentration of ethidium bromide (Yeqc) (Figure 1). High SpanEtBr indexes
indicated increased capacity to accumulate ethidium bromide. The equilibrium concentration is the
concentration where the uptake of ethidium bromide by the cell equals its efflux and corresponds to
the first concentration that gives no more than 10 units of fluorescence at the end of the 60 min of the
accumulation assay (indicated by the red arrow on the graph). The results obtained for the strains
tested are shown in Table 2.
Table 2. Characterization of the M. tuberculosis strains according to their efflux capacity.
Strains
Efflux Activity
SpanEtBr RFFVP RFFTZ K tefflux50%
Suscep.
H37Rv 26.10 1.57 ± 0.02 0.77 ± 0.01 0.09 ± 0.008 7.94 ± 0.75
Mtb#1 29.42 1.04 ± 0.03 0.13 ± 0.02 0.09 ± 0.086 8.06 ± 0.63
Mtb#2 28.51 2.07 ± 0.09 1.18 ± 0.03 0.09 ± 0.003 7.77 ± 0.30
INHR
Mtb#3 14.07 0.59 ± 0.02 0.90 ± 0.04 0.06 ± 0.008 11.98 ± 1.81
Mtb#4 13.50 1.21 ± 0.02 0.13 ± 0.05 0.08 ± 0.004 8.95 ± 0.48
RIFR
Mtb#5 12.13 1.00 ± 0.03 0.41 ± 0.01 0.07 ± 0.009 8.55 ± 0.47
Mtb#6 13.50 2.31 ± 0.02 1.11 ± 0.01 0.12 ± 0.004 5.95 ± 0.21
Mtb#7 10.46 1.26 ± 0.06 0.13 ± 0.05 0.10 ± 0.0004 6.67 ± 0.02
Mtb#8 13.16 1.16 ± 0.03 0.28 ± 0.01 0.14 ± 0.004 4.39 ± 0.41
MDR
Mtb#9 22.39 1.62 ± 0.09 0.79 ± 0.04 0.11 ± 0.0006 6.49 ± 0.04
Mtb#11 7.45 1.31 ± 0.36 0.39 ± 0.06 0.12 ± 0.0057 5.90 ± 0.42
Mtb#12 8.86 0.71 ± 0.00 0.30 ± 0.09 0.05 ± 0.0011 14.06 ± 0.46
Mtb#13 11.74 2.18 ± 0.01 0.98 ± 0.02 0.10 ± 0.0095 7.25 ± 0.72
Mtb#14 12.19 1.21 ± 0.15 0.89 ± 0.06 0.09 ± 0.0036 8.08 ± 0.33
XDR
Mtb#16 13.56 1.15 ± 0.17 1.05 ± 0.01 0.10 ± 0.007 6.89 ± 0.69
Mtb#17 14.80 1.78 ± 0.22 0.91 ± 0.23 0.14 ± 0.022 4.99 ± 0.78
The effect of the efflux inhibitors on the accumulation of ethidium bromide was interpreted as follows: relative final
fluorescence (RFF) indexes above zero indicated that cells accumulate more ethidium bromide under the condition
used than those of the control (non-treated bacterial cells). RFF values above 1 indicate enhanced accumulation
of ethidium bromide in the presence of the efflux inhibitors. Each assay was performed in triplicate and the
results presented correspond to the average of three independent assays plus standard deviation (±SD) [19,32].
Ethidium bromide was used at 0.125 µg/mL for Mtb#2, Mtb#5, Mtb#9; 0.25 µg/mL for H37Rv, Mtb#1, Mtb#4, Mtb#6,
Mtb#7, Mtb#13, Mtb#14, Mtb#16, Mtb#17; and 0.5 µg/mL for Mtb#3, Mtb#8, Mtb#11, Mtb#12. Strains Mtb#10 and
Mtb#15 were not evaluated due to poor growth under the conditions required for these assays. The inhibitors were
tested at 1/2 or 1/4 MIC (see Material and Methods for details). EtBr, ethidium bromide; INH, isoniazid; K, efflux
rate constant; MDR, multidrug resistant; R, resistant; RIF, rifampicin; Suscep., susceptible; TZ, thioridazine; VP,
verapamil; XDR, extensively drug resistant.
The accumulation of ethidium bromide for the M. tuberculosis strains took place at concentrations
above 0.5 µg/mL for Mtb#3, Mtb#8, Mtb#11, and Mtb#12; 0.25 µg/mL for H37Rv, Mtb#1, Mtb#4,
Mtb#6, Mtb#7, Mtb#13, Mtb#14, Mtb#16, and Mtb#17; and 0.125 µg/mL for Mtb#2, Mtb#5, and Mtb#9.
Analysing the data presented in the Table 2, we can observe that the susceptible strains presented
higher SpanEtBr values than the drug resistant strains, which is indicative of an increased accumulation
of ethidium bromide at higher concentrations (lesser ability to efflux). Concerning the drug resistant
strains, there was no significant difference on the SpanEtBr values between the monoresistant strains
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and the M/XDR strains (Table 2). These results showed that the drug resistant strains (monoresistant
and M/XDR) can handle higher concentrations of ethidium bromide than the susceptible ones having
a higher efflux capacity.
Next, we compared the rate of accumulation of ethidium bromide in the presence of the efflux
inhibitors as an indirect method to evaluate the efflux capacity of these strains (Table 2; Figure 2A). For this
purpose, we selected verapamil and thioridazine, two well-known efflux inhibitors of M. tuberculosis efflux
systems [7,17,19,22,23,33], and determined the RFF indexes. The RFF index is measure of how effective
a compound is on the inhibition of ethidium bromide efflux (at a given concentration) by comparison
of the final fluorescence at the last time point (60 min) of the treated cells with the cells in presence
of only ethidium bromide. At the same time, high levels of inhibition, or high RFF values, indicate
higher efflux activity of the strain and vice versa. As showed in Table 2, verapamil promoted the
highest levels of accumulation of ethidium bromide (RFF > 1) in 14 out of 16 of the strains tested.
Thioridazine showed to be less potent in the inhibition of ethidium bromide efflux than verapamil as
previously described [17,33]. These results indicated that all strains have active efflux systems that can
be inhibited by verapamil and, in less extent, by thioridazine.
Finally, to directly compare the efflux capacity of each strain, we further determined the efflux
rate constant, or K value, and the tefflux50% that corresponds to the time required for the cells to
extrude half of the preloaded dye (Table 2). To preload the cells with ethidium bromide, we selected
verapamil. Shown in Figure 2B are the results for selected strains on each of the drug resistance
categories. The efflux rate constants obtained for the 14 strains, whose efflux activity could be inhibited
by verapamil at high levels (RFF > 1), varied between 0.07 and 0.14. For the two strains with reduced
efflux activity, Mtb#3 and Mtb#12, the efflux rate constants were 0.06 and 0.05, respectively.
Concordantly, these strains were the ones that showed the slowest efflux rates as they took
more time to extrude half of the preloaded dye; strain Mtb#3 took 11.98 min and Mtb#12 took
14.06 min. On the other hand, the tefflux50% of the remaining strains was between 4.39 min and 8.95 min,
where Mtb#8 had the lowest tefflux50% and Mtb#4 had the higher tefflux50%. No correlation could be
observed between the different drug susceptibility profiles of the strains tested and the effect of both
compounds on the ethidium bromide efflux inhibition confirming the results obtained on the ethidium
bromide accumulation assays.
Overall, the results showed that (i) all strains presented efflux activity as a short-term stress
response to drugs, and (ii) the drug resistant strains presented increased capacity to handle higher
concentrations of toxic compounds, in this case, ethidium bromide, when compared with the
susceptible strains, revealing an enhanced efflux capacity independently of their resistance phenotype.
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Figure 2. Accumulation and efflux of ethidium bromide of the M. tuberculosis strains. (A) Accumulation of ethidium bromide in the presence of efflux inhibitors. In these 
cases, the strains were loaded with 0.25 µg/mL of ethidium bromide in the presence of verapamil or thioridazine at ½ MIC; (B) Efflux of ethidium bromide. Strains were 
loaded with ethidium bromide at 0.25 µg/mL; efflux took place in the presence of glucose which was inhibited by verapamil at ½ MIC.
Figure 2. Accumulation and efflux of ethidium bromide of the M. tuberculosis strains. (A) Accumulation of ethidium bromide in the presence of efflux inhibitors.
In these cases, the strains were loaded with 0.25 µg/mL of ethidium bromide in the presence of verapamil or thioridazine at 12 MIC; (B) Efflux of ethidium bromide.
Strains were loaded with ethidium bromide at 0.25 µg/mL; efflux took place in the presence of glucose which was inhibited by verapamil at 12 MIC.
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2.2. Effect of Efflux Inhibitors on the Resistance Levels to Rifampicin and Isoniazid
The MICs of the antibiotics and the efflux inhibitors for the M. tuberculosis strains included in
this study are summarized in Table 1. All the strains carried mutations in katG or inhA genes that
have been described to be involved in the resistance to isoniazid, mutations in the rpoB gene which
are associated with resistance to rifampicin, or both. The MICs of isoniazid for the strains presenting
the mutation S315T in katG are between 10 and 20 µg/mL contrasting with the MICs presented by
strains with mutations in inhA promotor (0.4 µg/mL) or inhA promotor plus ORF (Open Reading
Frame) mutations (3 µg/mL). Regarding rifampicin, the strains with mutations in rpoB presented
MICs between 20 µg/mL and 640 µg/mL. The MICs of both efflux inhibitors remained practically
unchanged among all strains (one dilution noted).
Subsequently, the effect of verapamil and thioridazine on the susceptibility levels of these strains
was evaluated (Table 3). Verapamil increased the susceptibility to isoniazid in 8/11 strains and to
rifampicin in 8/13 strains. In both cases, all the strains were at least MDR. Thioridazine showed a
weaker effect, increasing the susceptibility to isoniazid in 5/11 strains and to rifampicin in 3/13 strains,
all of them MDR. Comparing the data gathered for the monoresistant strains with the data of the MDR
strains, it was noticed that verapamil and thioridazine were more effective in reducing the resistance
levels of the M/XDR strains than of the monoresistant strains. This data indicated that the M/XDR
strains presented a more prolonged response to drugs mediated by efflux as observed by the effect of
verapamil on the susceptibility levels of isoniazid and rifampicin of these strains.
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Table 3. Synergistic effect between the efflux inhibitors and the antituberculosis drugs against the
M. tuberculosis strains determined by qDST.
Strain
MIC (µg/mL) MIC (µg/mL)
INH INH + VP INH + TZ RIF RIF + VP RIF + TZ
0.1 1 3 10 0.1 1 3 10 1 4 20 1 4 20
Suscep.
H37Rv 0.1 S - - - - - - - 1 S - - - - -
Mtb1 0.1 S - - - - - - - 1 S - - - - -
Mtb2 0.1 S - - - - - - - 1 S - - - - -
INHR
Mtb3 10 R R R S R R R S 1 - - - - - -
Mtb4 1 R S S S R S S S 1 - - - - - -
RIFR
Mtb5 0.1 - - - - - - - - 340 R R R R R R
Mtb6 0.1 - - - - - - - - 320 R R R R R R
Mtb7 0.1 - - - - - - - - 320 R R R R R R
Mtb8 0.1 - - - - - - - - 640 R R R R R R
MDR
Mtb9 3 R S S - R S S - 20 R S S R S S
Mtb10 3 R R S - R R S - 20 S S S S S S
Mtb11 10 R R S S R R R S 640 R R R R R R
Mtb12 10 R R S S R R S S 160 R R S R R R
Mtb13 3 R S S - R S S - 320 R R S R R R
Mtb14 20 R R R S R R S S 320 R R S R R R
XDR
Mtb15 20 R S S S R R R R 80 R R S R R S
Mtb16 3 R S S - R S S - 320 R R S R R R
Mtb17 3 R S S - R R S - 320 R R S R R R
INH, isoniazid; MDR, multidrug resistant; RIF, rifampicin; XDR, extensively drug resistant; VP, verapamil; TZ,
thioridazine; suscep or S, susceptible; R, resistant; MIC, minimum inhibitory concentration. The lowest concentration
of antibiotic tested corresponded to the critical concentration of each drug; the highest concentration tested was
the one that defines high-level resistance according to the qDST procedure (see Material and Methods for details).
Highlighted in red-bold type letter are the changes in the susceptibility (R to S) of the strain to the respective
antibiotic at the concentration tested in the presence of the efflux inhibitor. -, not tested.
Nevertheless, although the resistance levels could not be reduced in the monoresistant strains,
a synergistic effect was observed. The inhibition of growth of the monoresistant strains in presence
of isoniazid or rifampicin in combination with the inhibitors showed a delay of 1 to 3 days between
the tube containing the antibiotic plus the efflux inhibitor and the tube containing only the antibiotic
(data not shown). The synergistic effect depended on the drug combination and the concentration of
antibiotics tested, and demonstrates the existence of efflux activity in these strains but at lower levels
compared to the M/XDR strains.
Analysing the data collected in Tables 1–3, no correlation could be found between the genotype
and the efflux activity of these strains.
3. Discussion
With the growing body of knowledge about the contribution of efflux activity to M. tuberculosis
drug resistance, increased attention has been given to the use of efflux inhibitors as adjuvants of
tuberculosis therapy [7,8,34]. In previous works, we showed that M. tuberculosis drug resistance levels
are a balance between the presence of a mutation in the genes coding the drug target and active
efflux [18]. We observed that strains presenting the same mutation conferring antibiotic resistance
had different MICs and that the different resistance levels found could be reduced by efflux inhibitors.
Although full susceptibility was not restored, the existence of a broad-spectrum synergistic interaction
between antibiotics and efflux inhibitors was shown. However, we also noticed that the efflux
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inhibitors tested were significantly more effective against the M/XDR strains once compared with their
monoresistant counterparts. An evident question posed by these results is why the efflux inhibitors
are more effective on M/XDR strains. We hypothesized that the efficacy of the efflux inhibitors could
be strain-dependent, i.e., it may depend on the (i) genetic background or (ii) type of mutation in the
genes associated with resistance. To answer this question, in this study we investigated the effect of
the efflux inhibitors verapamil and thioridazine on the efflux levels of a panel of M. tuberculosis clinical
strains susceptible, isoniazid and rifampicin monoresistant, and M/XDR, in order to describe how the
efflux activity modulates the levels of resistance in strains presenting different phylogenetic lineages
and drug-resistance associated mutations.
The strains selected were the M. tuberculosis H37Rv, a worldwide used laboratory reference
strain fully susceptible to the first- and second-line antibiotics, and a panel of 17 clinical strains
differing on their phylogenetic origins, drug susceptibilities, and drug resistance associated mutations.
Firstly, we characterized all the M. tuberculosis strains according to their efflux capacity by real-time
fluorometry to analyse the short-term efflux-mediated responses to the presence of toxic compounds
measuring the cells response via efflux of ethidium bromide. With this method, we detected and
measured the efflux activity in all strains. This activity could be inhibited in the presence of verapamil,
and less efficiently by thioridazine, regardless of the phenotype or genotype of the strain in study.
The efflux assays clearly demonstrated that all the clinical strains, susceptible or resistant, presented
a faster, very rapid, and non-specific efflux-mediated short-term response, when compared with the
drug-naïve laboratory strain H37Rv, allowing the cells to cope in the presence of toxic compounds,
as previous seen on laboratory efflux-induced strains [19].
Concomitantly, the determination of the MICs of the antibiotics in the presence of the efflux
inhibitors provided information regarding the efflux-mediated long-term response of the cells to the
presence of noxious compounds, like ethidium bromide or antibiotics. Verapamil and thioridazine
were able to reduce the resistance levels of isoniazid, rifampicin, or both in the M/XDR strains, and in
particular it was possible to reverse the resistance to rifampicin in one of the MDR strains (Mtb#10).
Interestingly, the same kind of results were not observed for the monoresistant strains. No reduction
of the MICs in the presence of the efflux inhibitors was observed for the rifampicin or isoniazid
monoresistant strains. Despite the absence of a reduction in the antibiotic resistance levels in the
presence of the efflux inhibitors, a synergic effect between the efflux inhibitors and the antibiotics was
noted through the evaluation of the delay in the time to detection (TTD) of growth, demonstrating some
positive drug interaction, as expected by the presence of active efflux systems in these strains, as we
have highlighted before. Efflux activity in the monoresistant strains occurs at lower levels compared
to the M/XDR strains but both maintain it as a long-term stress response to drugs. Clearly, in the
M/XDR strains this activity is increased, contributes to an overall high-level resistance to isoniazid
and rifampicin, and can be reduced by the efflux inhibitors. These findings provide further evidence
on the role of efflux as a global stress response in M. tuberculosis and corroborate the previous notion
that M. tuberculosis clinical strains are primed to efflux toxic compounds [19].
Moreover, the data obtained showed that the efflux activity and the effect of the efflux inhibitors
does not depend on the strain genetic background and mutation(s) associated with drug resistance.
The rifampicin resistance levels were reduced from 320 µg/mL to 20 µg/mL in four M/XDR strains
harbouring the S531L rpoB mutation but not in the two rifampicin monoresistant strains presenting the
same mutation. Also, the rifampicin resistance of the MDR strain Mtb#10, presenting the mutation
H526Y on rpoB, was reversed from 20 µg/mL to 1 µg/mL in the presence of verapamil and thioridazine,
but not in the rifampicin monoresistant strain (Mtb#6) that carried the same mutation. The same
results were observed for the C-15T mutation on the inhA promoter between the M/XDR strains
and the isoniazid monoresistant strain presenting the same mutation. Overall, these results are in
concordance with those obtained with the real-time fluorometry assays (evaluation of the short-term
efflux response), where it was shown that the efflux activity and the effect of the efflux inhibitors on
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this activity is independent on the drug-resistant associated mutations of the strains, but with the
M/XDR strains recording higher levels of efflux activity.
Mutations such as the S315T in katG, C-15T in inhA promoter, and S531L in rpoB are predominant
in M. tuberculosis clinical isolates and have been associated with successful transmission [35–37].
These mutations are the most frequently found in clinical isolates [38], meaning that the M. tuberculosis
population within the host may be undergoing adaptive evolution to improve bacterial fitness and
efflux contribute for their survival and epidemiological success.
4. Materials and Methods
4.1. M. tuberculosis Strains
The strains studied are described in Table 1. These strains are part of the culture collection
of the Grupo de Micobactérias, Unidade de Microbiologia Médica, of the Instituto de Higiene e
Medicina Tropical (IHMT), Universidade NOVA de Lisboa (UNL). The panel of M. tuberculosis strains
studied was selected according to their susceptibility pattern and the presence of the most common
mutations associated with resistance to isoniazid and rifampicin in order to include susceptible,
isoniazid monoresistant, rifampicin monoresistant, MDR, and XDR. Informed consent was not required
for this study since it is a retrospective study from which all patient identification was unlinked from
the results, and no patient information was collected. M. tuberculosis H37Rv ATCC27294T was obtained
from the American Type Culture Collection (Manassas, VA, USA) and was included as control strain.
4.2. Antimicrobials and Reagents
The antibiotics isoniazid and rifampicin, the efflux inhibitors verapamil and thioridazine, the efflux
substrate ethidium bromide (EtBr), Tween 80, phosphate buffered saline (PBS), dimethyl sulfoxide
(DMSO), and glucose, were obtained from Sigma-Aldrich (St. Louis, MO, USA). Rifampicin was
prepared in DMSO, while the remaining drugs were prepared in sterile deionized water. The stock
solutions were aliquoted and stored at −20 ◦C and the working solutions freshly prepared on the day
of the experiment. The lyophilized drugs (BACTEC MGIT 960 SIRE and PZA kits; SIRE, streptomycin,
isoniazid, rifampicin, ethambutol; PZA, pyrazinamide) used in the standard susceptibility testing
were purchased from Becton Dickinson (Diagnostic Systems, Sparks, MD, USA) and the stock
solutions prepared as per the manufacturer’s instructions. BD Difco Middlebrook 7H9, BD BBL
OADC (oleic acid/albumin/dextrose/catalase) supplement and the Mycobacteria Growth Indicator
Tubes (MGITs) were from Becton Dickinson.
4.3. Susceptibility Testing
4.3.1. Growth of the Strains
For first-line susceptibility testing, MIC determination, and synergism assays, the M. tuberculosis
strains were inoculated in MGITs tubes supplemented with 10% OADC and incubated at 37 ◦C in
the BACTEC MGIT 960 (MGIT 960) system until they reached 100–200 growth units (GUs) and were
used directly for testing. Cultures with 200 < GU < 2000 were diluted to 100–200 GU with a sterile
saline solution and used for testing. Growth of the cultures was monitored with the Epicenter V5.80A
software equipped with the TB eXIST module (Becton Dickinson).
4.3.2. First-Line Drug Susceptibility Testing
The MGIT 960 was used for first-line drug susceptibility testing according to the manufacturer’s
instructions. The MGIT tubes were inoculated with 0.8 mL of OADC, 0.1 mL of the antibiotic at the
critical concentrations (0.1 µg/mL for isoniazid, 1 µg/mL for rifampicin, 1 µg/mL for streptomycin,
5 µg/mL for ethambutol, 100 µg/mL for pyrazinamide) and 0.5 mL of the suspension of the strain.
For preparation of the drug-free proportional control, the strain suspension was diluted 1:100 (1:10 for
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PZA) with a sterile saline solution and 0.5 mL inoculated in the tube. The results were interpreted as
follows: if the GU of the tubes containing the drug were >100 when the proportional control reached
400 GU, they were considered to be resistant to the respective concentration. If the GU of the tube
containing the drug was <100, they were considered susceptible [39].
4.3.3. MIC Determination of Antibiotics and Efflux Inhibitors
MIC determination of the antibiotics and efflux inhibitors was performed within the MGIT
960 and the Epicenter V5.80A/TB eXIST software. The inoculum of the strains and the MGIT tubes
were prepared as described above. At the time of testing, two-fold serial dilutions were prepared to
achieve the desired concentrations and 0.1 mL added to the corresponding drug-containing tubes.
For the proportion testing it was prepared two drug-free controls: the absolute control (1:1) and the
proportional control (1:100). The MIC was considered as the lowest concentration with GU < 100 when
the drug-free proportional control tube reached a GU value of 400.
4.3.4. Quantitative Drug Susceptibility Testing of Antibiotics in Presence and Absence of Inhibitors
Quantitative drug susceptibility testing of rifampicin and isoniazid conducted using the MGIT
960 and the Epicenter V5.80A/TB eXIST. Isoniazid was tested at 0.1, 1, 3, and 10 µg/mL and rifampicin
at 1, 4, and 20 µg/mL. For the quantification of the antibiotic resistance levels of each strain, the results
were interpreted as per Cambau et al. [38] as follows: isoniazid low-level resistance when resistant (R)
at 0.1 and susceptible (S) at 1 µg/mL; isoniazid high-level resistance when R ≥ 1; rifampicin low-level
resistance when R at 4 and S at 20 µg/mL; rifampicin high-level resistance when R ≥ 20 µg/mL.
The preparation of the drug containing tubes and controls was done as described above. For the
susceptibility testing for the antibiotics in the presence of the inhibitors, the tubes containing 0.1 mL
of the antibiotics at the desired concentrations were inoculated with 0.1 mL of the inhibitor to a
final concentration of 1/2 or 1/4 their MIC, depending on the strain. These concentrations were
selected in order to not compromise the growth of the strains following the protocol described
above. The resistance levels for each combination (antibiotic + efflux inhibitor) were quantified as
describe above.
4.4. Ethidium Bromide Real-Time Fluorometry
To detect the accumulation and extrusion of ethidium bromide, a common substrate of several
efflux pumps, we applied a real-time fluorometric method using a Rotor-Gene 3000 thermocycler
(Corbett Research, Sydney, Australia) [31,40]. The assays were performed as previously described [19].
The strains were grown in 10 mL of MB7H9 medium, 10% OADC, and 0.05% Tween 80, at 37 ◦C,
without stirring, until they reached an approximate OD600 of 0.8. The cells were collected by
centrifugation at 2940× g, for 3 min at room temperature. The supernatant was discarded, the pellet
washed, resuspended in PBS, and centrifuged as before. This procedure was performed twice.
For the ethidium bromide accumulation assays, the washed cells were re-suspended in PBS and
the OD600 adjusted to 0.8. To determine the equilibrium concentration, i.e., the lowest concentration
of ethidium bromide that causes accumulation, 50 µL of the cell suspension was added to 0.2 mL
tubes containing different concentrations of ethidium bromide that ranged from 0.125 to 3 µg/mL.
The final OD600 of the bacterial suspension in the assay was 0.4. The assays were conducted at 37 ◦C in
a Rotor-Gene 3000, and the fluorescence of ethidium bromide was measured (530/585 nm) at the end
of each cycle of 60 s, for 60 min. After this, the effect of the efflux inhibitors verapamil and thioridazine
on the accumulation of ethidium bromide was evaluated for each strain. These assays were performed
like described above with each efflux inhibitor at 1/2 or 1/4 of the MIC and ethidium bromide at the
higher concentration that does not cause accumulation determined for each strain. To quantify the
effect of the inhibitors in the accumulation of ethidium bromide, for each strain we determined the
relative final fluorescence (RFF) as previously described [41]. RFF values above 0 indicated that cells
accumulate more ethidium bromide under the condition used than the non-treated cells. Each assay
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was performed in triplicate and the results presented correspond to the average of three independent
assays (±SD).
For the efflux assays, the washed cells were resuspended in PBS and the OD600 adjusted to 0.4.
The ethidium bromide loaded cells were prepared by incubating the cell suspension in the presence
of the highest concentration of ethidium bromide that does not cause accumulation and verapamil
at 1/2 (or 1/4) of the MIC at room temperature during 60 min. After EtBr accumulation, the cells
were collected by centrifugation at 2940× g during 3 min, room temperature, and resuspended in
PBS to an OD600nm of 0.8. Then, 50 µL of the suspension was added to 0.2 mL tubes containing
(1) PBS only; (2) PBS plus glucose, to a final concentration of 0.4%; (3) verapamil only; and (4) glucose
to a final concentration of 0.4% plus verapamil. The final OD600 of the bacterial suspension in
the assay was 0.4. The fluorescence of ethidium bromide was measured, as described above.
The fluorescence was acquired first, at the end of 15 s and at the end of every 30 s during the
following 30 min. The efflux activity was quantified by comparing the fluorescence data obtained
for the cells under conditions that allow maximum efflux (incubation at 37 ◦C in the presence
of glucose and absence of a compound) against the data from the control tube that contains the
ethidium-bromide-loaded cells under conditions that inhibit the efflux (with a compound and absence
of glucose). The normalized data (Y, fluorescence vs. X, time) was plotted using GraphPad Prism
(GraphPad Software, La Jolla, CA, USA) [42]. Ethidium bromide efflux curves were fitted using a
single exponential decay equation as follows: Y = (Y0 − Plateau) ∗ exp(−K ∗ X) + Plateau, where X
is the time, Y is the ethidium bromide efflux that starts at Y0 and decays to the plateau in one phase;
the plateau is Y at infinite times. The plateau has the same units as Y and the K or slope is the efflux
rate constant.
4.5. Genotypic Characterization of the Strains
(i) DNA extraction: Genomic DNA was extracted using the QIAamp DNA mini kit (QIAGEN,
GmbH, Hilden, Germany) according to the manufacturer’s instructions.
(ii) Screening of mutations: The most common mutations in rpoB, katG, and the inhA promoter were
screened using the system Genotype MTBDRplus V2 (Hain Lifescience GmbH, Nehren, Germany)
according to the manufacturer’s instructions.
(iii) DNA sequencing: The analysis of internal fragments of the genes katG, inhA, and rpoB was
performed according to Machado et al. [43].
(iv) Strain typing: Spoligotyping was performed as previously described [44]. Detection of the
hybridization patterns was carried out using the ECL Chemiluminescence Detection System
(GE Healthcare, Cleveland, OH, USA).
4.6. Statistical Analysis
Statistical analysis was carried out using the Student’s t-test. A * p value < 0.05 was considered
statistically significant and highly significant when ** p < 0.01 and *** p < 0.001 (two-tailed test).
5. Conclusions
The acquisition of drug resistance by the M. tuberculosis strains is frequently associated with a
decreased in the bacterial fitness and reduced transmissibility. Nevertheless, M. tuberculosis can evolve
and adapt to reduce the biological cost of MDR by the acquisition of compensatory mechanisms to
ameliorate the cost of its resistance, allowing its survival and spread in the population. The findings
gathered in this study emphasize the contribution of efflux activity in M. tuberculosis towards adaptive
evolution. The overactivity of efflux pumps should be considered when studding the impact of MDR
in the transmission dynamics and virulence of M. tuberculosis clinical strains. Drug resistance mediated
by efflux has become an important issue since it helps the bacteria to survive in the presence of
antimicrobial compounds. In this sense, the potential use of efflux inhibitors in combination with
antibiotics may be valuable as adjunct for a combined therapeutic approach. The overactivity of
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efflux pumps can influence the bacterial dynamics within the population in the presence of antibiotic
pressure, until mutations in the drug targets arise and establish in the population [19]. The final
resistance level is a combination between the efflux of the drug and the presence of the mutations [18].
This work complemented our previous findings now demonstrating how efflux activity modulates the
levels of drug resistance between monoresistant and M/XDR M. tuberculosis clinical strains allowing
the bacteria to survive for longer periods in the presence of noxious compounds.
Further studies into the mechanisms of drug resistance that alleviate the biological cost of drug
resistance will help to better understand the emergence, epidemiological success, and dissemination of
antimicrobial resistance in the clinical setting and also aid in its management and prevention.
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